CommentaryStatins and Diabetes: Current Perspectives and Implications for Clinicians
Section snippets
Acknowledgment
We are indebted to Angela Moscaritolo for her expert technical assistance.
References (10)
- et al.
Interpretation of the evidence for the efficacy and safety of statin therapy
Lancet
(2016) - et al.
Statins and risk of incident diabetes: a collaborative meta-analysis of randomized trials
Lancet
(2010) - et al.
Guidelines and guidance in lipid modification
Trends Cardiovasc Med
(2015) - et al.
Lipid modification in the treatment and prevention of cardiovascular diseases: emerging clinical and public health challenges
- et al.
Statistical association and causation: contributions of different types of evidence
JAMA
(2011)
Cited by (0)
Funding: None.
Conflict of Interest: CHH reported that he is funded by the Charles E. Schmidt College of Medicine of Florida Atlantic University; serves as an independent scientist in an advisory role to investigators and sponsors as Chair or Member of Data and Safety Monitoring Boards for Amgen, AstraZeneca, Bayer, Bristol Myers-Squibb, British Heart Foundation, Cadila, Canadian Institutes of Health Research, DalCor, Genzyme, Lilly, Regeneron, Sanofi, Sunovion and the Wellcome Foundation; to the US Food and Drug Administration, UpToDate, and to Pfizer and its legal counsel; receives royalties for authorship or editorship of 3 textbooks and as co-inventor on patents for inflammatory markers and cardiovascular disease that are held by Brigham and Women's Hospital; has an investment management relationship with the West-Bacon Group within SunTrust Investment Services, which has discretionary investment authority and does not own any common or preferred stock in any pharmaceutical or medical device company. BT reported no disclosures. MAP reported that he serves as a Consultant for Bayer, Boehringer Ingelheim, DalCor, Genzyme, Gilead, GlaxoSmithKline, Janssen, Lilly, Medicines Company, Merck, Novartis, Novo Nordisk, Relypsa, Sanofi, Teva and Thrasos; research grants from Novartis and Sanofi. Other: Stock options DalCor. The Brigham and Women's Hospital has patents for the use of inhibitors of the renin-angiotensin system in survivors of myocardial infarction with Novartis, with licensing agreement is irrevocably transferred to charity.
Authorship: All authors had a role in writing the manuscript.